C90.02 Multiple myeloma in relapse

Name of the Condition

• Multiple Myeloma in Relapse (ICD-10 Code: C90.02)

Summary

Multiple myeloma in relapse refers to the return of active disease after a period of remission or response to treatment. This occurs when abnormal plasma cells reemerge and begin to grow, leading to the recurrence of symptoms or laboratory abnormalities. Relapse indicates that the disease is no longer controlled and requires further intervention.

Causes

Relapse is driven by residual cancer cells that survived initial treatment. These cells may have developed resistance to therapy or reactivated due to genetic changes. The underlying cause of multiple myeloma itself involves genetic mutations in plasma cells, but the specific triggers for relapse are not fully understood.

Risk Factors

• Prior history of multiple myeloma.
• Incomplete response to initial treatment.
• High-risk genetic markers at diagnosis.
• Short duration of remission.
• Age (most common in individuals over 60).
• Family history of plasma cell disorders.

Symptoms

• Recurrence of bone pain (e.g., spine, ribs).
• Fatigue and weakness.
• Increased susceptibility to infections.
• Unexplained weight loss.
• Nausea or constipation.
• Hypercalcemia (elevated blood calcium levels).
• Kidney dysfunction (e.g., increased thirst, reduced urine output).

Diagnosis

Diagnosis involves confirming the return of active disease through blood tests (e.g., abnormal protein levels), urine tests (e.g., light chains), bone marrow biopsy (to detect plasma cell presence), and imaging (e.g., X-rays, MRI) to assess bone damage. Relapse is defined by specific laboratory or clinical criteria, such as rising M-protein levels or new bone lesions.

Treatment Options

• Chemotherapy to target cancerous cells.
• Targeted therapies (e.g., proteasome inhibitors, immunomodulatory drugs).
• Stem cell transplantation (if eligible).
• Radiation therapy for localized bone pain or lesions.
• Supportive care (e.g., bisphosphonates for bone health, hydration for kidney protection).

Prognosis and Follow-Up

Prognosis depends on factors like the timing of relapse, prior treatment response, and overall health. Regular monitoring (e.g., blood tests, imaging) is essential to detect progression early. Treatment may be adjusted based on relapse patterns and patient tolerance.

Complications

• Severe bone damage (fractures, spinal cord compression).
• Kidney failure.
• Recurrent infections.
• Hypercalcemia-related symptoms (e.g., confusion, dehydration).
• Anemia or bleeding disorders.

Lifestyle & Prevention

• Maintain a balanced diet to support overall health.
• Stay hydrated to protect kidney function.
• Engage in gentle exercise to preserve bone strength.
• Avoid smoking and limit alcohol.
• Follow up with healthcare providers as scheduled.

When to Seek Professional Help

Seek immediate care for:

• Sudden severe bone pain.
• Signs of infection (e.g., fever, chills).
• Changes in urination or kidney function.
• Neurological symptoms (e.g., numbness, weakness).
• Unexplained weight loss or fatigue.

Tips for Medical Coders

Code C90.02 is used when multiple myeloma has relapsed after a period of remission or response to treatment. Documentation should specify the relapse event, including clinical or laboratory evidence of disease recurrence. Ensure the timing of relapse relative to prior treatment is clear to support accurate coding.